Form 4: Contineum Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Carmine N. Stengone, CEO and President and a Director of Contineum Therapeutics, Inc., sold 2,500 shares of common stock on August 3, 2026 for $16.01 per share.
Summary
- Option exercise/conversion: acquired 2,500 Class A Common Stock at $1.01 ($2,525) on August 3, 2026; holds 19,717 after (Direct).
- Open-market sale: disposed of 2,500 Class A Common Stock at $16.01 ($40,029) on August 3, 2026; holds 17,217 after (Direct).
- Option exercise/conversion: disposed of 2,500 Stock Option (right to buy) on August 3, 2026; holds 276,930 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $40,029 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Carmine N. Stengone — Director, Officer (CEO and President)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-03 | Option exercise/conversion | Class A Common Stock | 2,500 | $1 | $2.5K | 19,717 |
| 2026-08-03 | Open-market sale | Class A Common Stock | 2,500 | $16 | $40.0K | 17,217 |
| 2026-08-03 | Option exercise/conversion | Stock Option (right to buy) | 2,500 | — | — | 276,930 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-03 | Option exercise/conversion (2,500 shares) |
| 2026-08-03 | Open-market sale (2,500 shares) |
| 2026-08-03 | Option exercise/conversion (2,500 shares) |
Keywords
insider transaction, Form 4, CTNM, Contineum Therapeutics, Inc., bearish, Carmine N. Stengone
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.